

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/584,810	GRAHAM ET AL.	
	Examiner	Art Unit	
	Zachariah Lucas	1648	

All Participants:

(1) Zachariah Lucas.

(2) Melissa B. Wenk.

Status of Application: _____

(3) _____

(4) _____

Date of Interview: 24 October 2007

Time: _____

Type of Interview:

- ☒ Telephonic
☐ Video Conference
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No
 If Yes, provide a brief description:

Part I.

Rejection(s) discussed:
 NA

Claims discussed:
 1, 7, 8, 15, 18


Prior art documents discussed:
 NA

Part II.

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:
 See Continuation Sheet

Part III.

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.


 (Examiner/SPE Signature)

 (Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The examiner indicated that the application would be in condition for allowance upon limitation of claims 1 and 7 to embodiments wherein the amino acid sequence comprises, or the nucleic acid sequence encodes, the full-length sequence of SEQ ID NO: 1; claims 15 and 18 were amended to indicate that SEQ ID NO: 1 is the polymerase, rather than is encoding it. Further, it was agreed to amend claim 8 to indicate that the nucleotide sequence of that claim encodes an amino acid sequence consisting of SEQ ID NO: 1 (thereby providing a further limitation to claim 7). It was also agreed that the generic language "RNA purification kit" would be added for the QIAGEN product on page 8 of the application, and that each of the amendments would be made by Examiner's Amendment.